Pharma major Lupin launches Tacrolimus capsules USP
Lupin Limited announced on Wednesday that it has launched Tacrolimus capsules USP, 0.5 mg, 1 mg, and 5 mg, after Lupin’s alliance partner Concord Biotech received approval for its ANDA from United States Food & Drug Administration (USFDA).
Reacting to this, the stock of Lupin rose 1.39 per cent and made an intraday high of Rs 907.65 per share.
Tacrolimus capsules USP are the generic equivalent of Prograf Capsules of Astellas Pharma US. It is indicated for the prophylaxis of organ rejection, in adult patients, receiving an allogeneic kidney transplant, liver transplant, and heart transplant, and in pediatric patients, receiving allogeneic liver transplants.
The stock of Lupin has recovered by 79.84 per cent from its sharp decline in March 2020.
The stock has a 52-week high and a 52-week low of Rs 1,121.85 per share and Rs 505 per share, respectively. According to BSE data, the stock traded at a P/E multiple of 46.75 and a price-to-book ratio of 2.26.
Lupin is one of the world's largest manufacturers of Tuberculosis drugs. Today, it has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, anti-infective, and non-steroidal anti-inflammatory drugs.
The share price of the company closed at Rs 895, down by 0.02 per cent per share on BSE.